938
RITA BAMNELA et al.
4(4'-Bromophenyl)-6-(4''-chlorophenyl)-1-acetyl 5,6- dihydropyrimidine-2-thiol (3d)
IR (KBr) in cm-1 : 2542.38 (S-H str), 1703.20 (N-C=O str), 1587.47 (C=C str), 1576.89
(C=N str), 619.17 (Ar-Br str), 750.01 (Ar-Cl str); H1 NMR (CDCl3) δ (ppm) : 1.54 (ꢀ, 1H, S-H),
2.06 (ꢀ, 3H, N-CO-CH3), 5.53 (d, 1H, H-C6 pyrimidine), 6.72 (d, 1H, H-C5 pyrimidine),
7.15 - 7.60 (m, 8H, Ar-H).
4(4'-Bromophenyl)-6-(2'-chlorophenyl)-1-acetyl, 5,6-dihydropyrimidine-2-thiol (3e)
IR (KBr) in cm-1 : 2596.27 (S-H str), 1681.98 (N-C=O str), 1583.61 (C=C str), 1568.18
(C=N str), 513.08 (Ar-Br str), 702.11 (Ar-Cl str). H1 NMR (CDCl3) δ(ppm) : 1.56 (ꢀ, 1H, S-H),
2.08 (ꢀ 3H, N-CO-CH3), 5.55 (d, 1H, H-C6 pyrimidine), 6.73 (d, 1H, H-C5 pyrimidine),
7.16 - 7.62 (m, 8H, Ar-H).
4(4'-Bromophenyl)-6-(4''-dimethylaminophenyl)-1-acetyl-5,6-dihydropyrimidine-2-thiol (3f)
IR (KBr) in cm-1 : 2548.05 (S-H str), 1680.99 (N-C=O str), 1583.61 (C=C str), 1508.38 (C=N str).
H1NMR (CDCl3) δ(ppm) : 1.57 (ꢀ, 1H, S-H), 2.08 (δ, 3H, N-COCH3), 3.03 (ꢀ, 6H, N(CH3)2), 5.54
(d, 1H, H-C6 pyrimidine), 6.74 (d, 1H, H-C5 pyrimidine), 7.19-7.68 (m, 8H, Ar-H).
4(4'-Bromophenyl)-6-(2'-nitrophenyl)-1-acetyl-5, 6-dihydropyrimidine-2-thiol (3g)
IR (KBr) in cm-1 : 2580.77 (S-H str), 1680.98 (N-C=O str), 1605.09 (C=C str), 1560.08
(C=N str), 560.02 (Ar-Br str), 1590.25 (Ar-NO2 Asym str), 1340.22 (Ar-NO2 sym str).
H1NMR (CDCl3) δ(ppm) : 1.60 (ꢀ, 1H, S-H), 2.10 (ꢀ, 3H, N-COCH3), 5.60 (d, 1H, H-C6
pyrimidine), 6.78 (d, 1H, H-C5 pyrimidine), 7.20-8.10 (m, 8H, Ar-H).
4(4'-Bromophenyl)-6-(3'-nitrophenyl)-1-acetyl- 5,6 - dihydropyrimidine-2- thiol (3h)
IR (KBr) in cm-1 : 2580.77 (S-H str), 1680.90 (N-C=O str), 1605.08 (C=C str), 1560.04
(C=N str), 560.00 (Ar-Br str), 1540.00 (Ar-NO2 Asym. str), 1320.99 (Ar-NO2 sym. str).
H1NMR (CDCl3) δ (ppm) : 1.52 (ꢀ, 1H, S-H), 2.05 (ꢀ, 3H, N-COCH3), 5.58 (d, 1H, H-C6
pyrimidine), 6.74 (d, 1H, H-C5 pyrimidine), 7.27-8.12 (m, 8H, Ar-H).
4(4'-Bromophenyl)-6-furyl-1-acetyl-5,6-dihydro- pyrimidine- 2-thiol (3i)
IR (KBr) in cm-1 : 2569.27 (S-H str), 1683.91 (N-C=O str), 1585.54 (C=C str), 1489.01
(C=N str), 569.02 (Ar-Br str), 1072.46 (Furyl ring C-O-C str), 2980.04 (C-H str), H1 NMR
(CDCl3) δ (ppm) : 1.61 (ꢀ, 1H, S-H), 2.10 (ꢀ, 3H, N-COCH3), 5.59 (d, 1H, H-C6
pyrimidine), 6.76 (d, 1H, H-C5 pyrimidine), 7.20-7.78 (m, 7H, Ar-H).
4(4'-Bromophenyl)-6-(2'-hydroxyphenyl)-1-acetyl- 5,6-dihydropyrmidine-2-thiol (3j)
IR(KBr) in cm-1 : 2600.01 (S-H str), 1680.88 (N-C=O str), 1585.55 (C=C str), 1568.18 (C=N
str), 599.88 (Ar-Br str), 3400.01 (Ar-OH), H1NMR (CDCl3) δ (ppm) : 1.61 (ꢀ, 1H, S-H), 2.09 (ꢀ,
3H, N-COCH3), 4.99 (ꢀ, 1H, Ar-OH), 5.61 (d, 1H, H-C6 pyrimidine), 6.75 (d, 1H, H-C5
pyrimidine), 7.18-7.78 (m, 8H, Ar-H).
Antimicrobial activity
The synthesized compounds (3a-j) were screened for their in vitro antimicrobial activity
against, Bacillus subtilis, Escherichia coli, Klebsiella pneumoniae and Staphylococcus
aureus and antifungal activity against, Aspergillus niger, Aspergillus flavus, Trichoderma
viride, Candida albicans by measuring the zone of inhibition in mm. The antimicrobial
activity was performed by standard filter paper disc diffusion method16-17 and zone of
inhibition is reported in the Table 3. Streptomycin and nystatin were used as standard drug
for antibacterial and antifungal activities respectively. Nutrient agar was employed as culture
medium and DMSO, was used as solvent.